Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial

Publication | Open Access

DOI Full Paper Access

173

Citations

References

2023

Year

Sumanta K. Pal, Laurence Albigès, Piotr Tomczak, Cristina Suárez, Martin H. Voss, Guillermo de Velasco, Jad Chahoud, Anastasia Mochalova, Giuseppe Procopio, Hakim Mahammedi,

The Lancet

UrologyGenitourinary CancerMedicineImmune Checkpoint InhibitorRenal Cell CarcinomaPharmacotherapyCancer TreatmentImmunotherapyOncologyRadiation Oncology